New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
10:04 EDTHS, MOH, UNH, WCG, AGP, AET, HUM, WLP, CNC, HNT, GILD, CIGilead criticized by insurance trade group for 'astronomical' hep C drug price
In a post to its Coverage blog, America's Health Insurance Plans stated that Hepatitis C treatment Sovaldi has shown "tremendous results" and is the "kind of medical innovation we need to sustain," but claims the drug’s maker, Gilead (GILD), is taking "advantage of a lack of competition – has priced it at an astronomical level that is not sustainable for consumers, innovation, or society." America’s Health Insurance Plans, or AHIP, is the national trade association representing the health insurance industry. Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP). Reference Link
News For GILD;HUM;UNH;HNT;AET;MOH;CNC;AGP;HS;WLP;WCG;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
09:05 EDTUNHInsperity, UnitedHealthcare extend contract through 2019
Insperity (NSP) announced that it has extended its arrangement for medical and dental coverage through 2019 with UnitedHealthcare, a UnitedHealth Group (UNH) company. This arrangement reflects the dedication of both companies to offer the best health care and health care reform solutions in the marketplace. Insperity has partnered with UnitedHealthcare as its leading health insurance carrier since January 2002. The majority of Insperity's corporate and worksite employees have health coverage with UnitedHealthcare.
August 28, 2015
11:04 EDTCIOptions with increasing implied volatility
Subscribe for More Information
August 26, 2015
17:06 EDTGILDGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
12:02 EDTAETAetna, MemorialCare announce accountable care collaboration in California
Subscribe for More Information
08:04 EDTUNHHCA Holdings UnitedHealth weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
August 25, 2015
19:34 EDTGILDExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
August 24, 2015
18:02 EDTUNHS&P 500 enters correction territory amid global growth concerns
Subscribe for More Information
13:36 EDTGILDBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 21, 2015
08:13 EDTUNHUnitedHealth has reached attractive entry point, says BMO Capital
Subscribe for More Information
August 20, 2015
16:34 EDTGILDGilead MAA for HIV regimen has been fully validated by EMA
Gilead Sciences announced that the company's Marketing Authorization Application, MAA, for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg has been fully validated and is now under evaluation by the European Medicines Agency, EMA. Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. "With this validation, R/F/TAF is now the third TAF-based filing under review by the EMA as we advance a portfolio of new treatment options that may offer high efficacy and favorable safety profiles," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "The R/F/TAF filing also represents the next step in our collaboration with Janssen to develop HIV treatments that potentially meet the diverse needs of people living with HIV."
08:03 EDTCNCCentene subsidiary wins statewide foster care contract
Subscribe for More Information
August 18, 2015
07:57 EDTUNH, WCGMagellan Iowa loss largely priced into shares, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use